JPS6049200B2 - peptide - Google Patents

peptide

Info

Publication number
JPS6049200B2
JPS6049200B2 JP52104083A JP10408377A JPS6049200B2 JP S6049200 B2 JPS6049200 B2 JP S6049200B2 JP 52104083 A JP52104083 A JP 52104083A JP 10408377 A JP10408377 A JP 10408377A JP S6049200 B2 JPS6049200 B2 JP S6049200B2
Authority
JP
Japan
Prior art keywords
arg
pro
acid
tyr
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP52104083A
Other languages
Japanese (ja)
Other versions
JPS5439072A (en
Inventor
政彦 藤野
千恵子 北田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP52104083A priority Critical patent/JPS6049200B2/en
Publication of JPS5439072A publication Critical patent/JPS5439072A/en
Publication of JPS6049200B2 publication Critical patent/JPS6049200B2/en
Expired legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Description

【発明の詳細な説明】 本発明は、肥満細胞に働いて脱顆粒作用を示す新規ペプ
タイドに関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a novel peptide that acts on mast cells and exhibits a degranulation effect.

従来から、肥満細胞脱顆粒作用を示すペプタイドは多く
知られているが、それらの殆んどは平滑筋収縮作用を示
す。
Many peptides have been known that exhibit mast cell degranulation activity, but most of them exhibit smooth muscle contraction activity.

最近、中嶋らによつて発表されたグラニユリベリンーR
(Granuliberin−R)は、ツチガエルの
皮膚から分離され、その構造はH−Phe−Gly−P
he−Leu−Pro−ne−Tyr−Arg−Arg
−Pro一Ala−Ser−Ni(、と決定されたペプ
タイドであり、これは肥満細胞脱顆粒作用を示すが、平
滑筋に対して全く作用を示さす、生理的に好ましいもの
である。
Recently, Granule Liberine-R was announced by Nakajima et al.
(Granuliberin-R) is isolated from the skin of the Japanese frog, and its structure is H-Phe-Gly-P.
he-Leu-Pro-ne-Tyr-Arg-Arg
-Pro-Ala-Ser-Ni, which is a physiologically preferred peptide that exhibits mast cell degranulation effects but no effect on smooth muscle.

本発明者らは、グラニユリベリンーRの脱顆粒作用に必
要な化学構造を知り、より低分子量の作用物質を探す目
的て作用の本体を追求したところ、その活性中心はC−
末端側に存在することを知見し、これをもとに各種のペ
プタイドを合成し、さらに究した結果、本発明を完成し
た。
The present inventors learned the chemical structure necessary for the degranulation action of Granulelibellin-R, and pursued the main body of the action with the aim of searching for a lower molecular weight active substance, and found that the active center is C-
We discovered that it exists on the terminal side, synthesized various peptides based on this, and as a result of further investigation, we completed the present invention.

すなわち、本発明は、式H−ne−Tyr−Arg−A
rg−X−R(I)〔式中、XはPro)Pro−Al
a又はPro−Ala−Serを、RはOH又はNH。
That is, the present invention provides the formula H-ne-Tyr-Arg-A
rg-X-R(I) [wherein X is Pro) Pro-Al
a or Pro-Ala-Ser, and R is OH or NH.

を、それぞれ表わす。〕で表わされるペプタイドてある
。本明細書において、アミノ酸、ペプタイド、保護基等
に関する表示は、IUPAC−IUBCommissi
−ononBiologicalNomenclatu
reによる略記法あるいは当該分野における慣用略号に
基づいており、それらの例を次に示す。
, respectively. ] There is a peptide represented by In this specification, indications regarding amino acids, peptides, protecting groups, etc. are based on IUPAC-IUBCommissi
-ononBiologicalNomenclatu
It is based on the abbreviation re or common abbreviations in the field, examples of which are shown below.

■e:イソロイシン Tyr:チロシン Arg:アルギニン Pro:プロリン A1a :アラニン Ser:セリン z :カルボベンゾキシ基 BOC:ターシヤリーブチルオキシカルボニル基NO2
:ニトロ基 OMe:メチルエステル OB21:ベンジルエステル HONE:N−ハイドロキシー5−ノルボルネンー2、
3−ジカルボキシイミドONB:同エステル ■℃ :N、N’−ジシクロヘキシルカルボジイミドま
た薄層クロマトグラフィー(シリカゲルプレート)のR
f値は次に示す溶媒系を使用した。
■e: Isoleucine Tyr: Tyrosine Arg: Arginine Pro: Proline A1a: Alanine Ser: Serine z: Carbobenzoxy group BOC: Tert-butyloxycarbonyl group NO2
: Nitro group OMe: Methyl ester OB21: Benzyl ester HONE: N-hydroxy 5-norbornene-2,
3-Dicarboximide ONB: Same ester ■°C: N,N'-dicyclohexylcarbodiimide Also, R of thin layer chromatography (silica gel plate)
The following solvent system was used for the f value.

Rfl:クロロホルムリメタノール:氷酢酸
(9:1:0.5)Rf2:酢酸エチルニピリジンニ氷
酢酸:水 (60:20:6:10)Rf3:
酢酸エチルニ氷酢酸:n−ブタノールニ水 (
1:1:1:1) Rf4:n−ブタノールニピリジンニ氷酢酸:水
(30:20:6:24) 本発明の化合物(1)は、ペプタイド縮合反応の常套手
段と官能性基の適宜な保護手段とを適宜使用して製造し
うる。
Rfl: Chloroformrimethanol: Glacial acetic acid
(9:1:0.5) Rf2: Ethylnipyridine acetate diglacial acetic acid: water (60:20:6:10) Rf3:
Ethyl acetate diglacial acetic acid: n-butanol dihydrate (
1:1:1:1) Rf4: n-butanol pyridine diglacial acetic acid: water
(30:20:6:24) Compound (1) of the present invention can be produced by appropriately using a conventional method of peptide condensation reaction and a suitable means for protecting a functional group.

か)るペプタイド縮合反応や保護手段は、たとえば゛T
hePeptides゛、第1巻(1966)、Sch
rOderandLubke著、AcademicPr
ess.sNewYOrk.sU.S.Aあるいは′6
ペプタイド合成゛泉屋や著、丸善株式会社(197師)
に記載されており、より具体的には、縮合反応としては
、たとえばアジド法、クロライド法、酸無水物法、DC
C法、活性エステル法、ウッドワード法、カルボジイミ
ダゾール法、酸化還元法、DCC/アティテブ(HON
B..HOBt..HOSu)法などがあげられる。ま
た官能性基の保護法としては、たとえばαーアミノ基の
保護基として、カルボベンゾキシ、t−ブチルオキシカ
ルボニル、t−アミルオキシカルボニル、イソボルニル
オキシカルボニル、p−メトキシベンジルオキシカルボ
ニル、2−クロルーベンジルオキシカルボニル、アダマ
ンチルオキシカルボニル、トリフルオロアセチル、フタ
リル、ホルミル、0−ニトロフエニルスルフエニル、ジ
フエニルホスフイノチオイルなどがあげられる。
Such peptide condensation reactions and protection measures are, for example,
hePeptides, Volume 1 (1966), Sch
rOderandLubke, AcademicPr
ess. sNewYOrk. sU. S. A or '6
Peptide synthesis by Izumiyaya, Maruzen Co., Ltd. (197 master)
More specifically, condensation reactions include, for example, the azide method, chloride method, acid anhydride method, DC
C method, active ester method, Woodward method, carbodiimidazole method, redox method, DCC/Atiteb (HON
B. .. HOBt. .. Examples include the HOSu) method. Further, as a method for protecting a functional group, for example, as a protecting group for an α-amino group, carbobenzoxy, t-butyloxycarbonyl, t-amyloxycarbonyl, isobornyloxycarbonyl, p-methoxybenzyloxycarbonyl, 2- Examples include chlorobenzyloxycarbonyl, adamantyloxycarbonyl, trifluoroacetyl, phthalyl, formyl, 0-nitrophenylsulfenyl, diphenylphosphinothioyl, and the like.

アルギニンのグアニジノ基の保護基は必ずしも必要では
ないが、たとえばニトロ基、トシル基、カルボベンゾキ
シ、イソポ゛ルニルオキシカルボニル、アダマンチルオ
キシカルボニル、p−メトキシベンゼルスルホニル等で
保護してもよい。またカルボキシル基は、たとえば金属
塩(例、ナトリウム、カリウム、リチウム塩等)、t−
アルキルアミン塩(例、トリエチルアミン、N−メチル
モルホリン、N−エチルモルホリン等)あるい・はエス
テル(例、メチル、エチル、プロピル、t−ブチル、t
−アミル、ベンジル、p−ニトロベンジル等のエステル
)の形で保護することもできる。さらにセリンの水酸基
、チロシンの水酸基は共に保護する必要はないが、固相
合成法においては、ベンジル、t−ブチル、2−クロロ
ベンジル等のエーテルで保護することがあるが、液相合
成に於いても保護基として上記のエーテル等が使用7さ
れる場合がある。本ペプタイド(1)の製造工程中、縮
合反応は溶媒の存在下で行なう。
Although a protecting group for the guanidino group of arginine is not necessarily required, it may be protected with, for example, a nitro group, tosyl group, carbobenzoxy, isopolyloxycarbonyl, adamantyloxycarbonyl, p-methoxybenzelsulfonyl, or the like. In addition, carboxyl groups are, for example, metal salts (e.g., sodium, potassium, lithium salts, etc.), t-
Alkylamine salts (e.g., triethylamine, N-methylmorpholine, N-ethylmorpholine, etc.) or esters (e.g., methyl, ethyl, propyl, t-butyl, t-
-amyl, benzyl, p-nitrobenzyl and other esters). Furthermore, it is not necessary to protect both the hydroxyl group of serine and the hydroxyl group of tyrosine, but in solid phase synthesis, they may be protected with ethers such as benzyl, t-butyl, 2-chlorobenzyl, etc., but in liquid phase synthesis, In some cases, the above-mentioned ethers and the like are used as protecting groups. During the production process of this peptide (1), the condensation reaction is carried out in the presence of a solvent.

溶媒としては縮合反応に使用しうることが知られている
ものから適宜選択されうる。たとえば無水または含水の
ジメチルホOルムアミド、ジメチルスルホキサイド、ピ
リジン、クロロホルム、ジオキサン、ジクロルメタン、
テトラハイドロフラン、酢酸エチルあるいはこれらの適
宜の混合物などがあげられる。反応温度は、ペプタイド
結合形成反応に一般に使用され5る通常約−30゜C〜
約60゜Cの範囲から適宜選択される。結合形成反応と
しては、主として原料カルボキシル基の活性化によつて
行われるが、たとえば酸無水物、アジド、活性エステル
(例、ペンタクロロフェニル、2,4,5−トリクロロ
フエノール、2,4ージニトロフェノール、p−ニトロ
フェノール、シアノメチルアルコール、N−ハイドロキ
シー5−ノルボルネンー2,3−ジカルボキシイミド、
N−ハイドロキシサクシンイミド、N−ハイドロキシフ
タルイミド、N−ハイドロキシベンズトリアゾールとの
エステル)などがあげられる外に、たとえばジシクロヘ
キシルカルボイミド、カルボジイミダゾール等の脱水剤
も使用される。本縮合反応終了後、生成物は一般に保護
基を有しているため、それは常法によつて離脱される。
The solvent may be appropriately selected from those known to be usable in the condensation reaction. For example, anhydrous or hydrous dimethylformamide, dimethyl sulfoxide, pyridine, chloroform, dioxane, dichloromethane,
Examples include tetrahydrofuran, ethyl acetate, and appropriate mixtures thereof. The reaction temperature is generally about -30°C to 50°C, which is generally used for peptide bond-forming reactions.
The temperature is appropriately selected from a range of about 60°C. The bond-forming reaction is mainly carried out by activating the carboxyl group of the raw material. , p-nitrophenol, cyanomethyl alcohol, N-hydroxy 5-norbornene-2,3-dicarboximide,
In addition to N-hydroxysuccinimide, N-hydroxyphthalimide, esters with N-hydroxybenztriazole), dehydrating agents such as dicyclohexylcarboimide and carbodiimidazole are also used. After the condensation reaction is completed, the product generally has a protecting group, which is removed by a conventional method.

かかる常法としては、たとえば、保護基を有する化合物
(1)を、還元反応、溶媒分解(ソルポリシス)に付す
ことにより行なわれる。還元反応としては、パラジウム
黒、パラジウムー炭素、白金等の触媒を用いる水素添加
、液体アンモニア中金属ナトリウムによる還元など、ソ
ルポリシスとしては、トリフルオロ酢酸、フッ化水素、
メタンスルホン酸等の強酸によるソルポリシスなどがあ
げられる。
Such a conventional method is carried out, for example, by subjecting the compound (1) having a protecting group to a reduction reaction or solvent decomposition (solpolysis). Reduction reactions include hydrogenation using catalysts such as palladium black, palladium-carbon, and platinum, reduction with metallic sodium in liquid ammonia, and solpolysis using trifluoroacetic acid, hydrogen fluoride,
Examples include solpolysis using strong acids such as methanesulfonic acid.

上記のようにして製造されたペプチド(1)は、反応終
了混合物から、ペプチドの分離手段、抽出、分配、カラ
ムクロマトグラフィーなどによつて採取できる。
Peptide (1) produced as described above can be collected from the reaction mixture by peptide separation means, extraction, distribution, column chromatography, etc.

ペブタイド(1)は、アルギニン残基を有するので、一
般には塩の形で採取される。
Since peptide (1) has an arginine residue, it is generally collected in the form of a salt.

塩を形成しうる酸としては、たとえば、塩酸、臭化水素
酸、硝酸、硫酸、リン酸などの無機酸、あるいはたとえ
ばギ酸、酢酸、プロピオン酸、乳酸、クエン酸、シウ酸
、マレイン酸、フマール酸、酒石酸などの有機酸などが
あげられる。本発明のペプタイド(1)は、動物の肥満
細胞(マストセル)に対して作用し、肥満細胞から顆粒
を放出せしめる作用があり、これにともなつてヒスタミ
ンを放出するため、抗ヒスタミン剤、抗,アレルギー剤
等の検索のための試薬として用いることができる。
Acids which can form salts include, for example, inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, or for example formic acid, acetic acid, propionic acid, lactic acid, citric acid, cylic acid, maleic acid, fumaric acid. Examples include organic acids such as acid and tartaric acid. The peptide (1) of the present invention acts on animal mast cells and has the effect of causing the mast cells to release granules, and along with this, releases histamine, so it can be used as an antihistamine, anti-allergic agent, etc. It can be used as a reagent for searches such as

該試薬として用いる場合の具体例を以下に挙げる。Specific examples of use as the reagent are listed below.

すなわち、参考例に具体的に説明する方法で啼乳動物の
肥満細胞を分離し、この肥満細胞を1×1σ個程度を適
当なメデユームにけんだくせしめ、全量を約1m1とし
て、1何も入れないもの、2化合物(1)を入れたもの
、3化合物(1)とスクリーニングに供する化合物の適
当量とを加えたもの、の3種類の試薬液を作る。これら
を、そ−れぞれ、3rCで1紛間〜2吟間加温し、反応
終了後氷水中に浸して、反応を停止せしめる。遠心分離
器にかけて、その上清液を100℃、10分間加温し、
再び遠心分離器にかけた後、上澄液中のヒスタミン含量
を計つて、比較することにより、スクリーニングに供し
た化合物の抗ヒスタミン遊離活性を調べることができる
。ペプタイド(1)を構成するアミノ酸残基に関し、光
学活性体がありうる場合は、L一体が作用効果の点から
好ましい。
That is, mast cells of mammals are separated by the method specifically explained in the reference example, and about 1 x 1σ of these mast cells are suspended in a suitable medium, and the total volume is about 1 ml, and 1 ml is added. Three types of reagent solutions are prepared: one without, one containing two compounds (1), and one containing three compounds (1) and an appropriate amount of the compound to be subjected to screening. Each of these is heated at 3 rC for 1 to 2 minutes, and after the reaction is completed, it is immersed in ice water to stop the reaction. Centrifuge and heat the supernatant at 100°C for 10 minutes.
After centrifuging again, the histamine content in the supernatant is measured and compared to determine the antihistamine release activity of the compound subjected to screening. Regarding the amino acid residues constituting the peptide (1), if an optically active form is possible, L-integrated forms are preferable from the viewpoint of action and effect.

以下の実施例、参考例において、アミノ酸に関し、光学
活性体は特に明示しない場合にはL一体を示すものとす
る。
In the following Examples and Reference Examples, regarding amino acids, the optically active form is assumed to be an L-unit unless otherwise specified.

実施例1 H−■e−Tyr−Arg−Arg−PrO−0Hの製
造(1)BOC−Tyr−Ar−g(NO2)−Ar−
g(NO2)−PrO一0CH3Z−Arg(NO2)
−Arg(NO2)−PrO−0CH3(R.Schw
yzerandH.KappeIerlHeIveti
cachlmlCaACta..外1550(1963
))3.7ダを25%臭化水素一氷酢酸10m1に溶か
し、室温で9紛間かきまぜる。
Example 1 Production of H-■e-Tyr-Arg-Arg-PrO-0H (1) BOC-Tyr-Ar-g(NO2)-Ar-
g(NO2)-PrO-0CH3Z-Arg(NO2)
-Arg(NO2)-PrO-0CH3(R.Schw
yzerandH. KappeIerlHeIveti
cahlmlCaACta. .. Outside 1550 (1963
)) Dissolve 3.7 Da in 10 ml of 25% hydrogen bromide, monoglacial acetic acid, and stir at room temperature.

これに乾燥エーテル100m1を加え、生じる沈殿をろ
取して乾燥する。この粉末をジメチルホルムアミド6m
1に溶解し、氷冷下トリエチルアミン1.4mtとBO
C−Tyr′−ONB2.2yを加えて1満間室温てか
きませる。不溶物をろ去し、溶媒を減圧で留去し、酢酸
エチルを加えて粉末とし、ろ取する。これを含水ジメチ
ルホルムアミドより再沈殿し、さらにメタノ−ルー酢酸
エチルより再沈殿して精製する。収量3.43y(86
%)、融点144−146精C1〔α〕芭0−40.7
(c=0.4、メタノール)、Rfl=0.0訊RP=
0.61元素分析C32H5OOl2N2・H2Oとし
て計算値:C47.28;H6.45;N2O.68実
測値:C47.54;H6.33;N2O.52(2)
BOC−11e−Tyr−Arg(NO2)−Arg(
NO,)一PrO−0cH3B0C−Tyr−Arg(
NO2)−Arg(NO2)−PrO−0CH,2.0
yをアニソール1.35wL1とトリフルオロ酢酸10
m1に溶解し、室温で2紛間かきまぜる。
100 ml of dry ether is added to this, and the resulting precipitate is collected by filtration and dried. Add this powder to 6 m of dimethylformamide.
1 and 1.4 mt of triethylamine and BO under ice cooling.
Add 2.2y of C-Tyr'-ONB and stir at room temperature for 1 full hour. Insoluble matters are removed by filtration, the solvent is distilled off under reduced pressure, ethyl acetate is added to form a powder, and the powder is collected by filtration. This is purified by reprecipitation from aqueous dimethylformamide and further reprecipitation from methanol-ethyl acetate. Yield 3.43y (86
%), melting point 144-146 Sei C1 [α] 0-40.7
(c=0.4, methanol), Rfl=0.0cmRP=
Calculated value as 0.61 elemental analysis C32H5OOl2N2.H2O: C47.28; H6.45; N2O. 68 actual value: C47.54; H6.33; N2O. 52(2)
BOC-11e-Tyr-Arg(NO2)-Arg(
NO,)-PrO-0cH3B0C-Tyr-Arg(
NO2)-Arg(NO2)-PrO-0CH, 2.0
y is anisole 1.35wL1 and trifluoroacetic acid 10
Dissolve in ml and stir at room temperature.

トリフルオロ酢酸を減圧で留去し、残留物にエーテルを
加えて粉末とし、これをろ取する。乾燥後、ジメチルホ
ルムアミド15mLに溶解し、これにトリエチルアミン
0.35m1とBOC−11e−ONBl.2gを加え
てm時間かき混せる。溶媒を留去し、酢酸エチルを加え
て粉末としてろ取し、これを含水メタノール再沈殿する
。収量1.9f(84%)、融点120℃(分解)、〔
α〕?−43.0((c=0.飄メタノール)、Rf2
=0.伝RP=0.60元素分析C38H6lOl3N
l3・H2Oとして計算値:C49.29;H6.86
;Nl9.67実測値:C49.54;H6.87;N
l9.98(3)BOC−11e−Tyr−Arg(N
O2)−Ar′g(NO2)ノ −PrO−0HB
0C−11e−Tyr−Arg(NO2)−Ar′g(
NO2)一PrO−0CH31.8yをメタノール4T
fLtと水2m1に溶かし、氷冷下、1規定水酸化ナト
リウム水4.7m1を加えて3吟間かき混せ、さらに室
温で4時間7かき混せる。
Trifluoroacetic acid was distilled off under reduced pressure, and ether was added to the residue to form a powder, which was collected by filtration. After drying, it was dissolved in 15 mL of dimethylformamide, and 0.35 ml of triethylamine and BOC-11e-ONBl. Add 2g and stir for m hours. The solvent is distilled off, ethyl acetate is added, the powder is collected by filtration, and the powder is reprecipitated with water-containing methanol. Yield 1.9f (84%), melting point 120°C (decomposition), [
α〕? -43.0 ((c=0.methanol), Rf2
=0. Legend RP=0.60 Elemental analysis C38H6lOl3N
Calculated value as l3・H2O: C49.29; H6.86
;Nl9.67 actual value:C49.54;H6.87;N
l9.98(3) BOC-11e-Tyr-Arg(N
O2)-Ar'g(NO2)-PrO-0HB
0C-11e-Tyr-Arg(NO2)-Ar'g(
NO2) -PrO-0CH31.8y in methanol 4T
Dissolve fLt in 2 ml of water, add 4.7 ml of 1N sodium hydroxide under ice-cooling, stir for 3 minutes, and further stir for 4 hours and 7 at room temperature.

氷冷して1規定塩酸水4.7mtを加えて中和し、析出
する沈殿をろ取し、水洗して乾燥する。1.3q0これ
を酢酸エチル−ピリジンー酢酸一水(106:30:9
:15)の混合溶媒に溶解し、同溶媒でつめたシリカゲ
ルのカラム(4×4Crft)に流し込み、同溶媒で溶
出する。
Cool on ice and neutralize by adding 4.7 mt of 1N hydrochloric acid, filter the precipitate, wash with water, and dry. 1.3q0 of this was mixed with ethyl acetate-pyridine-acetic acid monohydrate (106:30:9
:15), poured into a silica gel column (4×4 Crft) filled with the same solvent, and eluted with the same solvent.

74〜1困1Lの溶出区分を集め、溶媒を減圧留去し、
エーテルを加えて粉末としてろ取する。
74 to 1 L of elution fraction was collected, the solvent was distilled off under reduced pressure,
Add ether and filter as a powder.

収量1.08y1融点143てC(分解)、Rf2=0
.511〔α〕芭0−35.8=0.飄メタノール)元
素分析C37H59Ol3・H2Oとして計算値:C4
8.73:H6.74;Nl9.97実測値:C48.
8O;H6.8O;Nl9.94(4)H−■e−Ty
r−Arg−Arg−PrO−0HB0C−11e−T
yr−Arg(NO2)−Ar−g(NO2)一PrO
−0H450mgを氷酢酸100m1に溶かし、パラジ
ウム黒を触媒として接触還元する。
Yield 1.08y1 Melting point 143C (decomposition), Rf2=0
.. 511[α]Ba0-35.8=0. (Methanol) Elemental analysis Calculated value as C37H59Ol3・H2O: C4
8.73: H6.74; Nl9.97 Actual value: C48.
8O; H6.8O; Nl9.94 (4) H-■e-Ty
r-Arg-Arg-PrO-0HB0C-11e-T
yr-Arg(NO2)-Ar-g(NO2)-PrO
450 mg of -0H is dissolved in 100 ml of glacial acetic acid and catalytically reduced using palladium black as a catalyst.

8時間水添後、触媒をろ去して、ろ液を減圧乾固し、少
量の水にとかして凍結乾燥する。
After 8 hours of hydrogenation, the catalyst is filtered off, the filtrate is dried under reduced pressure, dissolved in a small amount of water, and freeze-dried.

収量410WL9。本品50mgをトリフルオロ酢酸2
m1にとかして室温15分後、減圧乾固し、残留物をセ
フアデツクスLH−20(フアルマシア●ファインケミ
カル社製)のカラム(1.0×91.5cff1)で3
規定酢酸水でゲルフイルトレーシンする。29〜40m
Lの分画を集め、凍結乾燥すると目的物28m9を得る
Yield 410WL9. 50mg of this product is mixed with 2 parts of trifluoroacetic acid.
After 15 minutes at room temperature, the residue was dried under reduced pressure, and the residue was purified with a column (1.0 x 91.5 cff1) of Cephadex LH-20 (manufactured by Pharmacia Fine Chemical Co., Ltd.).
Gel filtrate with normal acetic acid water. 29-40m
Fractions of L are collected and lyophilized to obtain the desired product 28m9.

Rf4=0.57(セルロースプレート)、〔α〕芭0
−18.1=(c=0.32、1規定酢酸水)実施例2 H−11e−Tyr−Arg−Ar′g−PrO−NH
2BOC−11e−Tyr−Arg(NO2)−Arg
(NO2)一PrO−0H900m9をジメチルホルム
アミド10m1にとかし、これにHONB2OOm9を
加えて氷冷下DCC25Omgを加える。
Rf4=0.57 (cellulose plate), [α] Bas 0
-18.1=(c=0.32, 1N acetic acid water) Example 2 H-11e-Tyr-Arg-Ar'g-PrO-NH
2BOC-11e-Tyr-Arg(NO2)-Arg
900m9 of (NO2)-PrO-0H is dissolved in 10ml of dimethylformamide, HONB2OOm9 is added thereto, and 250mg of DCC is added under ice-cooling.

氷冷下2時間、室温8時間かき混せた後、1規定アンモ
ニア−ジオキサン1.5m1を氷冷下加えて1満間かき
混ぜる。不溶物をろ去して減圧乾固し、酢酸エチル−ピ
リジンー酢酸一水(106:30:9:15)に溶解し
、同溶媒で充填したシリカゲルのカラム(4Cr11X
5C71)に展関し、同溶媒で溶出する。85〜175
m1の区分を集めて減圧乾固し、エーテルで粉末を集め
ろ取す−る。
After stirring for 2 hours under ice-cooling and 8 hours at room temperature, 1.5 ml of 1N ammonia-dioxane was added under ice-cooling and stirred for 1 full hour. The insoluble matter was filtered off and dried under reduced pressure, dissolved in ethyl acetate-pyridine-acetic acid monowater (106:30:9:15), and added to a silica gel column (4Cr11X) filled with the same solvent.
5C71) and elutes with the same solvent. 85-175
A fraction of m1 was collected and dried under reduced pressure, and the powder was collected and filtered with ether.

収量620mg。Rf2=0.62本品50mgを氷酢
酸100m1にとかし、パラジウム黒を触媒として、8
時間接触還元する。
Yield 620mg. Rf2=0.62 Dissolve 50mg of this product in 100ml of glacial acetic acid, use palladium black as a catalyst,
Time contact reduction.

触媒をろ去し減圧乾固し、トリフルオロ酢酸2m1を加
えて室温で2紛放置し、再び乾固して、セフアデツク.
スLH−20のカラム(1.0×91ゐG)に3規定一
酢酸水て展関する。30〜40mLの区分を集め凍結乾
燥すると目的物24m9を得る。
The catalyst was filtered off, dried under reduced pressure, added with 2 ml of trifluoroacetic acid, left to stand at room temperature, dried again, and dried in a cephadec.
A column of 3N monoacetic acid (1.0 x 91°G) was coated with 3N monoacetic acid. A portion of 30-40 mL is collected and freeze-dried to obtain 24m9 of the desired product.

Rf4=0.60(セルロースプレート)、〔α〕?−
1&4f(c=0.5.1規定−酢酸水)実施例3H−
Ne−Tyr−Arg−PrO−Ala−Ser−0H
の製造(1)BOC−Ala−Ser−0Bz1H−S
er−0Bz1●バラトルエンスルホン酸塩17.7y
をジオキサンと酢酸エチルの混合溶媒(1:1)150
m1に溶かし、トリエチルアミン7mLを加える。
Rf4=0.60 (cellulose plate), [α]? −
1&4f (c=0.5.1N-acetic acid water) Example 3H-
Ne-Tyr-Arg-PrO-Ala-Ser-0H
Production (1) BOC-Ala-Ser-0Bz1H-S
er-0Bz1●Balatoluenesulfonate 17.7y
mixed solvent of dioxane and ethyl acetate (1:1) 150
ml and add 7 mL of triethylamine.

これにBOC−Ala−CNBl7.5gを加えて、1
満間室温でかき混ぜる。溶媒を留去して、酢酸エチル7
00mtに溶かし、01規定塩酸水と5%炭酸水素ナト
リウム水で洗つて、無水硫酸ナトリウムで乾燥後、減圧
乾固する。残留物を酢酸エチルと石油エーテルから結晶
化し、ろ取する。)収量15.3ダ。融点50−52、
C1〔α〕芭0−27.3=1.0屯メタノール)、R
fl=0.71元素分析Cl8H26O6N2として計
算値:C59.OO;H7.l5;N7.65実測値:
C58.96;H7.O3;N7.6O門(2)BOC
−11e−Tyr−Arg(NO2)−Arg(NO2
)−PrO−Ala−Ser−0Bz1B0C−Ala
−Ser−0Bz11.8yを6ゐ規定塩酸一ジオキサ
ン3m1に溶かし、室温で1紛間放置する。
Add 7.5 g of BOC-Ala-CNBl to this and
Stir at room temperature. Distill the solvent and add ethyl acetate
00mt, washed with 01N hydrochloric acid water and 5% sodium bicarbonate water, dried over anhydrous sodium sulfate, and dried under reduced pressure. The residue is crystallized from ethyl acetate and petroleum ether and filtered off. ) Yield 15.3 Da. melting point 50-52,
C1 [α] 0-27.3 = 1.0 ton methanol), R
Calculated value as fl=0.71 elemental analysis Cl8H26O6N2: C59. OO;H7. l5; N7.65 actual value:
C58.96; H7. O3; N7.6O gate (2) BOC
-11e-Tyr-Arg(NO2)-Arg(NO2
)-PrO-Ala-Ser-0Bz1B0C-Ala
-Ser-0Bz11.8y was dissolved in 3 ml of 6°N hydrochloric acid monodioxane and left to stand at room temperature.

エーテルを加えて析出した結晶をろ取し、乾1燥する。
収量1.5y(100%)。本品515mgとBOC一
■e−T2pT−Arg(NO2)−Arg(NO2)
−PrO−0H1.07yをジメチルホルムアミド5n
tに溶かし、トリエチルアミン0.24mt(5H0N
B432wI9を加えて0℃に冷却し、■℃397Tn
9を加えて4時間かき混ぜ、更に室温て1′2!IF!
間かき混せる。ろ過して、ろ液を減圧留去し、残留物を
2%炭酸水素ナトリウム水で洗い、ついで1%酢酸水で
洗う。乾燥後、ジメチルホルムアミドに溶解し、酢酸エ
チルを加えて再沈殿して精製する。収量1.2y0融点
140℃(分解)、〔α〕芭0−35.7.(c=0.
75、氷酢酸)、Rf2=0.82(3)H−11e−
Tyr′−Arg−,Arg−PrO−Ala−Ser
一0H上記のBOC−■e−Tyr″−Ar′g(NO
2)−Arg(NO2)−PrO−Ala−Ser−0
Bz11yを氷酢酸200m1に溶かし、パラジウム黒
を触媒として8時間接触還元し、触媒をろ去し減圧乾固
する。
Ether was added and the precipitated crystals were collected by filtration and dried.
Yield 1.5y (100%). 515mg of this product and BOC-e-T2pT-Arg(NO2)-Arg(NO2)
-PrO-0H1.07y with dimethylformamide 5n
Dissolve in t and add 0.24 mt of triethylamine (5H0N
Add B432wI9, cool to 0℃, and heat to ■℃397Tn.
Add 9 and stir for 4 hours, then let it cool to room temperature for 1'2! IF!
Stir for a while. After filtration, the filtrate was evaporated under reduced pressure, and the residue was washed with 2% aqueous sodium bicarbonate and then with 1% aqueous acetic acid. After drying, it is purified by dissolving it in dimethylformamide and reprecipitating it by adding ethyl acetate. Yield 1.2y0 Melting point 140°C (decomposed), [α] Bass 0-35.7. (c=0.
75, glacial acetic acid), Rf2=0.82(3)H-11e-
Tyr'-Arg-, Arg-PrO-Ala-Ser
10H above BOC-■e-Tyr''-Ar'g(NO
2)-Arg(NO2)-PrO-Ala-Ser-0
Bz11y was dissolved in 200 ml of glacial acetic acid, catalytically reduced using palladium black as a catalyst for 8 hours, the catalyst was filtered off, and the mixture was dried under reduced pressure.

残留物を水10m1に溶かし、カルボキシメチルセルロ
ースのカラム(2.5×36cTn)に流入し、0.0
%規定と0.2規定の酢酸アンモニア水(700mt1
700mt)でグラジエント溶出する。355〜475
mLの溶出区分を集めて凍結乾燥する。
The residue was dissolved in 10 ml of water and applied to a column of carboxymethyl cellulose (2.5 x 36 cTn) at a concentration of 0.0
% normal and 0.2 normal acetic acid ammonia water (700 mt1
Gradient elution is performed at 700 mt). 355-475
The mL elution fractions are collected and lyophilized.

収量650m9。本品32m9をトリフルオロ酢酸2m
1に溶かし、10分間室温に放置し、減圧乾固する。
Yield 650m9. 32m9 of this product to 2m of trifluoroacetic acid
1, leave at room temperature for 10 minutes, and dry under reduced pressure.

残留物を3規定酢酸水に溶かし、セフアデツクスLH−
20のカラム(1.0×92CTf1)に3規定酢酸水
で展関する。32〜40m1の溶出区分を集め凍結乾燥
すると18m9の目的物を得る。
The residue was dissolved in 3N acetic acid water, and Sephadex LH-
20 columns (1.0 x 92 CTf1) with 3N acetic acid water. The elution fraction of 32-40 ml is collected and lyophilized to obtain 18 ml of target product.

〔α〕6分−50.5乾(c=0.2、N−酢酸)、R
r4=0.50(セルロース プレート)アミノ酸分析
値:Ar′G2.O8、SerO.98、Alal.O
O.,PrOl.O2、11EO.97、TyrO.9
9実施例4H−11e−Tyr−Arg−Arg−Pr
O−.Ala−Ser一NFI2の製造(1)Z−Al
a−Ser−NH2 Z−Ser−NH22.4yをメタノール200mLに
溶解し、パラジウム黒を触媒として4時間接触還元する
[α] 6 minutes-50.5 dry (c=0.2, N-acetic acid), R
r4=0.50 (cellulose plate) Amino acid analysis value: Ar'G2. O8, SerO. 98, Alal. O
O. , PrOl. O2, 11EO. 97, TyrO. 9
9 Example 4H-11e-Tyr-Arg-Arg-Pr
O-. Production of Ala-Ser-NFI2 (1) Z-Al
a-Ser-NH2 Z-Ser-NH22.4y is dissolved in 200 mL of methanol and catalytically reduced using palladium black as a catalyst for 4 hours.

触媒をろ去し、減圧乾固する。残留物をシメチルホルム
アミド30mtに溶かし、Z−Ala−ONB3.8ダ
を加えて室温で丘時間かき混ぜる。溶媒を減圧て留去し
、エーテルを加えて粉末をろ取し、メタノールで再結晶
する。収量2.0y0融点212−214ーC0〔α〕
?−10.5.(c=1.1、メタノール)、Rfl=
0.2、Rf2=0.75元素分析Cl4Hl9O5N
3として 計算値:C54.36;H6.l9;Nl3.59実測
値:C54.26:H6.23;Nl3.55(2)B
OC−11e−Tyr−Arg− (NO2)−Arg
(NO2)−PrO−Ala−Ser−NH2Z●Al
a−Ser−NH2l3Omgをメタノール50m1に
溶解し、パラジウム黒を触媒として4時間接触還元する
The catalyst was filtered off and dried under reduced pressure. The residue was dissolved in 30 mt of dimethylformamide, 3.8 mt of Z-Ala-ONB was added, and the mixture was stirred at room temperature for an hour. The solvent is distilled off under reduced pressure, ether is added, the powder is collected by filtration, and it is recrystallized from methanol. Yield 2.0y0 Melting point 212-214-C0 [α]
? -10.5. (c=1.1, methanol), Rfl=
0.2, Rf2=0.75 Elemental analysis Cl4Hl9O5N
Calculated value as 3: C54.36; H6. l9; Nl3.59 Actual value: C54.26: H6.23; Nl3.55 (2) B
OC-11e-Tyr-Arg- (NO2)-Arg
(NO2)-PrO-Ala-Ser-NH2Z●Al
A-Ser-NH2l3Omg was dissolved in 50ml of methanol and catalytically reduced using palladium black as a catalyst for 4 hours.

ろ過して、ろ液を減圧乾固し、残留物をジメチルホルム
アミド7m1にとかす。これに■℃−11e−Tyr−
Arg(NO2)−Arg(NO2)−PrO一0H3
13m9とHONBl26mgを加えて0℃に冷却し、
DCC87mgを加えて4時間かき混せる。更に室温で
w時間かき混せた後、ろ過してエーテルを加える。生す
る沈殿をろ取し、メタノールと酢酸エチルで再沈殿する
。収量196m9。融点157−160゜C(分解)、
〔α〕?5−48.3。(c=0.48、メタノール)
、Rf2=0.3伝RP=0.73元素分析C43H7
OO5Nl6・CH3OH−H2Oとして計算値:C4
7.99:H6.96;N2O.35実測値:C47.
58;H6.68;Nl9.98(3)H−11e−T
yT′−Arg−.Ar′g−PrO−Ala−Ser
一NH2BOC−11e−Tyr−Arg(NO2)−
Ar−g(NO2)−PrO−Ala−Ser−Nll
289mgをアニソール0.06mLを含むトリフルオ
ロ酢酸1m1にとかし、室温で3紛間放置する。
Filter, dry the filtrate under reduced pressure, and dissolve the residue in 7 ml of dimethylformamide. To this ■℃−11e−Tyr−
Arg(NO2)-Arg(NO2)-PrO-0H3
Add 13m9 and 26mg of HONBl and cool to 0°C.
Add 87 mg of DCC and stir for 4 hours. After further stirring at room temperature for w hours, filter and add ether. The resulting precipitate is collected by filtration and reprecipitated with methanol and ethyl acetate. Yield 196m9. Melting point 157-160°C (decomposition),
[α]? 5-48.3. (c=0.48, methanol)
, Rf2=0.3 DenRP=0.73 Elemental analysis C43H7
Calculated value as OO5Nl6・CH3OH-H2O: C4
7.99:H6.96;N2O. 35 Actual value: C47.
58; H6.68; Nl9.98 (3) H-11e-T
yT'-Arg-. Ar'g-PrO-Ala-Ser
-NH2BOC-11e-Tyr-Arg(NO2)-
Ar-g(NO2)-PrO-Ala-Ser-Nll
Dissolve 289 mg in 1 ml of trifluoroacetic acid containing 0.06 mL of anisole and leave at room temperature for 3 times.

トリフルオロ酢酸を留去し、エーテルを加えて粉末とし
てろ取する、767F!9。これを酢酸20m1に溶か
してパラジウム黒を触媒として接触還元する。触媒をろ
去して、減圧乾固する。残留物を1規定の酢酸水に溶か
してセフアデツクスLH−20のカラム(1.0×あ礪
)に1規定一酢酸水て展関する。31〜3f3m1の溶
出区分を集めて凍結乾燥すると24m9の目的物をうる
Trifluoroacetic acid is distilled off, ether is added, and the powder is collected by filtration, 767F! 9. This was dissolved in 20 ml of acetic acid and catalytically reduced using palladium black as a catalyst. The catalyst was filtered off and dried under reduced pressure. The residue was dissolved in 1N aqueous acetic acid and applied to a column of Sephadex LH-20 (1.0 x 100ml) with 1N monoacetic acid. When the elution fraction of 31 to 3f3ml is collected and freeze-dried, 24m9 of the target product is obtained.

〔α〕芭3−50.5j(c=0.44、1N一酢酸)
、Rf3=0.57(セルロース・プレート)、Rf4
=0.52(セルロース・プレート)アミノ酸分析Ar
gl.92、SerO.89.Alal.OO、PrO
l.Oll■El.OへTyrl.O2、NH2l.l
4実施例5H−11e−Tyr−Arg−Arg−Pr
O−Ala−NH2の製造(イ) BOC−11e−T
yr−Arg(NO2)−Ar−g(NO2)−PrO
−Ala−NH2の製造Z−Ala−NH2lllTn
g(0.5ミリモル)をメタノール50m1に溶かし、
パラジウム黒を触媒として室温で3時間還元する。
[α] Basa 3-50.5j (c=0.44, 1N monoacetic acid)
, Rf3=0.57 (cellulose plate), Rf4
=0.52 (cellulose plate) amino acid analysis Ar
gl. 92, SerO. 89. Alal. OO, PrO
l. Oll■El. O to Tyrl. O2, NH2l. l
4 Example 5H-11e-Tyr-Arg-Arg-Pr
Production of O-Ala-NH2 (a) BOC-11e-T
yr-Arg(NO2)-Ar-g(NO2)-PrO
-Production of Ala-NH2Z-Ala-NH2llllTn
Dissolve g (0.5 mmol) in 50 ml of methanol,
Reduction is carried out at room temperature for 3 hours using palladium black as a catalyst.

触媒をろ去し、メタノールを留去してH−Ala−NH
2を得る。これをBOC一■e−TyT−Arg(NO
2)−Arg(NO2)−PrO−0H268mg(0
.3ミリモル)とHONBlO8mg(0.6ミリモル
)とともにジメチルホルムアミド5m1に溶かし、氷冷
下に■℃82mg(0.4ミリモル)を加え4時間かき
まぜ、さらに室温て■時間かきませる。析出するウレア
をろ去して溶媒を留去し、残留物にエーテルを加えて粉
末としてろ取する。これをメタノールと酢酸エチルとか
ら再沈殿して精製し174TLg(60%)を得る。R
f2O.42(ロ) H−Ne−Tyr−Arg−Ar
g−PrO−Ala−NH2の製造BOC−11e−T
yr−Arg(NO2)−Ar′g(NO2)一PrO
−NH296mgをアニソール0.07m1とともにト
リフルオロ酢酸Lmlに溶かして室温て3紛置く。
The catalyst was filtered off, methanol was distilled off, and H-Ala-NH
Get 2. This is BOC-e-TyT-Arg (NO
2)-Arg(NO2)-PrO-0H268mg(0
.. 3 mmol) and 8 mg (0.6 mmol) of HONBlO were dissolved in 5 ml of dimethylformamide, and while cooling on ice, 82 mg (0.4 mmol) was added at ■°C and stirred for 4 hours, and further stirred at room temperature for ■ hours. Precipitated urea is removed by filtration, the solvent is distilled off, ether is added to the residue, and the powder is collected by filtration. This is purified by reprecipitation from methanol and ethyl acetate to obtain 174TLg (60%). R
f2O. 42 (b) H-Ne-Tyr-Arg-Ar
Production of g-PrO-Ala-NH2 BOC-11e-T
yr-Arg(NO2)-Ar'g(NO2)-PrO
-Dissolve 296 mg of NH together with 0.07 ml of anisole in L ml of trifluoroacetic acid and place 3 drops at room temperature.

トリフルオロ酢酸を留去し、エーテルを加えて粉末とし
てろ取する。これを酢酸20m1に溶かしてパラジウム
黒を触媒として5時間還元する。触媒をろ去し酢酸を留
去して残留物をセフアデツクス・LH−20(1.0×
85c7n)のカラムに付し1規定一酢酸で溶出する。
30−38m1の部分を集めて凍結乾燥し30mgを得
る。
Trifluoroacetic acid is distilled off, ether is added, and the powder is collected by filtration. This was dissolved in 20 ml of acetic acid and reduced for 5 hours using palladium black as a catalyst. The catalyst was removed by filtration, the acetic acid was distilled off, and the residue was purified by Sephadex LH-20 (1.0×
85c7n) column and eluted with 1N monoacetic acid.
Collect 30-38 ml portions and lyophilize to obtain 30 mg.

Rf4(セルロース)0.55アミノ酸分析値Argl
.96(2)、PrOl.O5(1)、Alal.O(
1)、11El.α1)、Tyr′0.98(1)、平
均回収率75%参考例: 化合物(1)のヒスタミン遊
離作用SPranglje−DaWIey系のラケツト
(体重240一280y..雄性、10−11週)をT
.J.Sullivanらの方法〔ジャーナル●オブ
イミユノロジー(JOUrrl2llOfImmunO
lOgy)、114巻、1473頁、197師〕に準じ
て処理し、肥満細胞(マスト・セル)のサスペンション
(1×1σ個/ML)を得る。
Rf4 (cellulose) 0.55 amino acid analysis value Argl
.. 96(2), PrOl. O5(1), Alal. O(
1), 11El. α1), Tyr' 0.98 (1), average recovery rate 75% Reference example: Histamine-releasing effect of compound (1)
.. J. Sullivan et al.'s method [Journal of
Immunology (JOUrrl2llOfImmunO
A suspension of mast cells (1×1σ cells/ML) is obtained.

肥満細胞サスペンション0.1mt(1x1(P個)に
化合物(1)を加え、反応液全量を1m1にする。
Add compound (1) to 0.1 mt (1 x 1 (P cells) of mast cell suspension, and make the total volume of the reaction solution 1 ml.

〔メデユームはNaCll5Orrlモル、KCl3.
7mモル、Na2HPO43rTlモル、K2HPO4
3.5mlモル、CaCl。lmモル、牛血清アルブミ
ン0.1%、ゼラチン0.1%、へバリン10単位/M
lPH6.5−6.6〕、37℃で15分間インキュベ
ートした後、氷水中に浸し、反応を停止せしめ、700
G110分間遠沈して上清液を100℃、1紛間煮沸し
、700y15分間遠心器にかけ、上澄液中のヒスタミ
ンをShOreらの方法〔ジャーナル●オブ●フアーマ
コロジー・アンド●エクスペリメンタル●セラピユーテ
イクス(JOurnalOfPharmacOlOgy
andExperimentalTllerapeut
ics)127巻、182頁、1959年〕に準じて、
0−PhthalaldehydeSpectrOph
OtOmetric法によつて定量した。化合物(1)
の作用を肥満細胞に対し特異な作用を有するといわれる
ニユーロテンシン(NeLlr′0−Tensin)と
比較した結果を表に示した。
[The medium is NaCl 5 Orrl mol, KCl 3.
7mmol, Na2HPO43rTlmol, K2HPO4
3.5 ml mol, CaCl. lmmol, bovine serum albumin 0.1%, gelatin 0.1%, hebalin 10 units/M
pH 6.5-6.6], incubated at 37°C for 15 minutes, immersed in ice water to stop the reaction,
The supernatant was centrifuged for 110 minutes, boiled at 100°C, centrifuged at 700y for 15 minutes, and the histamine in the supernatant was removed using the method of ShOre et al. [Journal of Pharmacology and Experimental ●Therapeutics (JournalOfPharmacOlOgy
andExperimentalTllerapeut
ics) volume 127, page 182, 1959],
0-PhthalaldehydeSpectrOph
It was quantified by OtOmetric method. Compound (1)
The table shows the results of a comparison of the effects of Neurotensin (NeLlr'0-Tensin), which is said to have a specific effect on mast cells.

Claims (1)

【特許請求の範囲】 1 式 H−Ile−Tyr−Arg−Arg−X−R〔式中、
XはPro、Pro−Ala又はPro−Ala−Se
rを、RはOH又はNH_2を、それぞれ表わす。 〕で表わされるペプタイド。
[Claims] 1 Formula H-Ile-Tyr-Arg-Arg-X-R [wherein,
X is Pro, Pro-Ala or Pro-Ala-Se
r and R represents OH or NH_2, respectively. ].
JP52104083A 1977-08-29 1977-08-29 peptide Expired JPS6049200B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP52104083A JPS6049200B2 (en) 1977-08-29 1977-08-29 peptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP52104083A JPS6049200B2 (en) 1977-08-29 1977-08-29 peptide

Publications (2)

Publication Number Publication Date
JPS5439072A JPS5439072A (en) 1979-03-24
JPS6049200B2 true JPS6049200B2 (en) 1985-10-31

Family

ID=14371236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52104083A Expired JPS6049200B2 (en) 1977-08-29 1977-08-29 peptide

Country Status (1)

Country Link
JP (1) JPS6049200B2 (en)

Also Published As

Publication number Publication date
JPS5439072A (en) 1979-03-24

Similar Documents

Publication Publication Date Title
Hofmann et al. Studies on Polypeptides. XXX. Synthetic Peptides Related to the N-Terminus of Bovine Pancreatic Ribonuclease (Positions 8-13) 1-4
US4100152A (en) Peptides
Hofmann et al. Studies on polypeptides. XXXIV. Enzymic properties of partially synthetic De (16-20)-and De (15-20)-ribonucleases S'1-3
SU700060A3 (en) Method of preparing peptides or salts
US4061625A (en) Novel chromogenic thrombin substrates
US3705140A (en) Peptides related to the c-terminal sequence of cck-pz and caerulein
EP2847210B1 (en) V1a receptor agonists
Inman et al. Synthesis of large haptenic compounds having a common functional group that permits covalent linkage to proteins, cell surfaces, and adsorbents
CA1187871A (en) Pharmacologically active peptides
Kopple et al. Reactivity of Cyclic Peptides. II. cyclo-L-Tyrosyl-L-histidyl and cyclo-L-Tyrosyltriglycyl-L-histidylglycyl
US4092304A (en) 4-Substituted enkephalin derivatives
JPS6049200B2 (en) peptide
US4169015A (en) Novel chromogenic thrombin substrates
Inouye et al. A synthesis of thyrotropin-releasing factor
US3792032A (en) Polypeptides related to the c-terminal heptapeptide of bombesin and alytesin
US3966701A (en) Fibrinogen peptide derivatives
CN109553658B (en) Ang- (1-7) aza polypeptide analogue, preparation method and application
SU659083A3 (en) Method of obtaining sulfate of octapeptideamide-terminal octapeptide of cholecystokinin-pancreazimin
Li et al. A new synthesis of a biologically active nonadecapeptide corresponding to the first ninetten amino acid residues of adrenocorticotropins
Johnson et al. The 4-(methylthio) phenyl ester for the synthesis of polypeptides of a known repeating sequence of amino acids. Synthesis of poly-(L-lysylglycyl) glycine 1-C14 ethyl ester hydrobromide
US4043994A (en) New pentapeptides and methods for their production
Moroder et al. Studies on cytochrome c. X. Synthesis of Nα‐benzyloxycarbonyl‐[Thr107]‐dotetracontapeptide (sequence 67–108) of baker's yeast iso‐1‐cytochrome c
Suli-Vargha et al. Synthesis and antitumor activity of N-terminal proline-containing peptide-(chloroethyl) nitrosoureas
Katsoyannis et al. Insulin Peptides IV. The Synthesis of a Protected Decapeptide Containing the C-Terminal Sequence of the A-Chain of Insulin
Camble et al. Polypeptides. L. Synthesis of a protected tritricontapeptide hydrazide corresponding to positions 48-80 of the primary structure of ribonuclease T1